PCM
PVLA

Prelude Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Prelude Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-18
Closed -$8K – 2227
2018
Q3 		$8K Sell
18
-9
-33% -$3.91K ﹤0.01% 1554
2018
Q2 		$11K Sell
27
-43
-61% -$20.5K ﹤0.01% 1474
2018
Q1 		$38K Buy
70
+54
+338% +$33.4K ﹤0.01% 1149
2017
Q4 		$10K Buy
+16
New +$7.44K ﹤0.01% 1208

Other funds holding PVLA

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Prelude Capital Management's PVLA Position: Q4 2018 in Review

Prelude Capital Management sold out of Palvella Therapeutics (PVLA) in Q4 2018, closing a stake of 18 shares — an estimated $8K sold.

Prelude Capital Management first reported a position in PVLA in Q4 2017 and held it in 4 quarters. The position peaked at $38K in Q1 2018. 98 funds tracked by Wall St. Rank hold PVLA as of Q4 2018.

  • Prelude Capital Management reported no remaining Palvella Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Prelude Capital Management sold 18 Palvella Therapeutics shares in Q4 2018, an estimated $8K.
  • Prelude Capital Management first reported a position in Palvella Therapeutics in Q4 2017 and held it in 4 quarters.
  • Prelude Capital Management's Palvella Therapeutics position peaked at $38K in Q1 2018.
  • 98 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2018.

Based on Prelude Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.